• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 3
  3. Author

Online ISSN: 2515-8260

Volume9, Issue3

External Ventriculostomy and Intraventricular Instillation Of Recombinant Tissue Plasminogen Activator For Management Of Spontaneous Intra-Ventricular Hemorrhage: A Prospective Study

    Dr. Sourabh Guria,Dr. Shubhamitra Chaudhuri,Dr. Shahid Iftekhar Sadique

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 5892-5901

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Aim: To evaluate external ventriculostomy and intraventricular instillation of recombinant tissue
plasminogen activator for management of spontaneous intra-ventricular hemorrhage.
Material and method:The present non-randomized prospective study was done in the
Department of Neurosurgery among 30 patients who underwent external ventriculostomy and
intraventricular instillation of recombinant tissue plasminogen activator at Bangur Institute Of
Neurosciences & SSKM HOSPITAL, IPGME&R, KOLKATA between April 2020 – August
2021. Various parameters studied were GOSE SCORE: 7 days------>30days------>90 days,
Ventriculitis: (0-180days) (y/n), 30 days survival (y/n), worsening hemorrhage during t/t till 72
hr. of last dose (y/n), worsening hemorrhage during t/t > 72 hr. of last dose (y/n), hydrocephalus
during follow up (y/n) and Qol (EQ5D) at 1 month and 3 months.
Results: Mortality was reported among 33.33% of the subjects after 3 months. After seven days,
good recovery was not found in any of the subject but after 1 month and 3 month, good recovery
was reported among 4 (13.33%) and 9 (30%) of the subjects respectively. After 3 months;
vegetative state, severe disability and moderate disability was found in 2, 7 and 2 subjects
respectively. There was significant decrease in clot volume (cc) after the intervention of external
ventriculostomy and intraventricular instillation of recombinant tissue plasminogen activator i.e.
it decreases from 38.23 to 8.11 after 5 days.
Conclusion:rtPAwas efficacious in decreasing the modified GOSE scoresand clot volume of all
study subjects at end of treatment. Ventriculitis was demonstrated only in six subjects
Keywords:
    IVH rtPA Mortality Ventriculitis
  • PDF (211 K)
  • XML
(2022). External Ventriculostomy and Intraventricular Instillation Of Recombinant Tissue Plasminogen Activator For Management Of Spontaneous Intra-Ventricular Hemorrhage: A Prospective Study. European Journal of Molecular & Clinical Medicine, 9(3), 5892-5901.
Dr. Sourabh Guria,Dr. Shubhamitra Chaudhuri,Dr. Shahid Iftekhar Sadique. "External Ventriculostomy and Intraventricular Instillation Of Recombinant Tissue Plasminogen Activator For Management Of Spontaneous Intra-Ventricular Hemorrhage: A Prospective Study". European Journal of Molecular & Clinical Medicine, 9, 3, 2022, 5892-5901.
(2022). 'External Ventriculostomy and Intraventricular Instillation Of Recombinant Tissue Plasminogen Activator For Management Of Spontaneous Intra-Ventricular Hemorrhage: A Prospective Study', European Journal of Molecular & Clinical Medicine, 9(3), pp. 5892-5901.
External Ventriculostomy and Intraventricular Instillation Of Recombinant Tissue Plasminogen Activator For Management Of Spontaneous Intra-Ventricular Hemorrhage: A Prospective Study. European Journal of Molecular & Clinical Medicine, 2022; 9(3): 5892-5901.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 80
  • PDF Download: 123
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus